Novo Nordisk says phase 3 data show denecimig cuts bleeding rates in hemophilia A extension study - NVO News | RalliesNovo Nordisk says phase 3 data show denecimig cuts bleeding rates in hemophilia A extension study
N
NVO• FRONTIER4 extension data support denecimig
- Novo Nordisk unveiled interim phase 3 FRONTIER4 extension data supporting denecimig (Mim8) safety and efficacy in hemophilia A prophylaxis.
- Denecimig is under FDA review following a September 2025 Biologics License Application filing.
- Study safety profile stayed consistent; injection-site reactions were 1.8%-2% of injections; no neutralizing antibodies were observed.
- Estimated mean annualized bleeding rates were 0.75 in adults/adolescents, 0.37 in children; 71% and 89% had zero treated bleeds.
